Genetic Factors in Breast Cancer Treatment Response

Breast cancer poses a significant global health challenge, with chemotherapy resistance affecting patient outcomes. This study, conducted in Burkina Faso, aimed to explore genetic factors, particularly the CHEK2 1100delC mutation, associated with breast cancer treatment response. From January 2020 to August 2022, a case-control study enrolled 78 patients, with 38 cases showing a poor response to chemotherapy and 40 controls exhibiting a good response. While the study found no CHEK2 1100delC mutations, it underscores the need for further research, particularly through sequencing methods, to enhance our understanding of breast cancer treatment responses.